Subscribe To
PCVX / Vaxcyte, Inc. (PCVX) Q4 2022 Earnings Call Transcript
PCVX News
By Seeking Alpha
August 17, 2023
Strong Financials And Pipeline Position Vaxcyte For Success
Vaxcyte, Inc. is a clinical-stage vaccine company developing high-fidelity vaccines for bacterial diseases. The company's Q2 2023 earnings report show more_horizontal
By Zacks Investment Research
May 29, 2023
Wall Street Analysts Think Vaxcyte, Inc. (PCVX) Could Surge 33.33%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 33.3% in Vaxcyte, Inc. (PCVX). While the effectiveness of thi more_horizontal
By Seeking Alpha
May 17, 2023
Vaxcyte: Positive Phase 2 Results Elevate Confidence In VAX-24's Potential
Vaxcyte is emerging as a leader in vaccine innovation, leveraging high-fidelity vaccines to combat bacterial diseases. The company's lead candidate, V more_horizontal
By Zacks Investment Research
April 18, 2023
Vaxcyte (PCVX) Up on Pneumococcal Conjugate Vaccine Data
Vaxcyte (PCVX) announces positive results from the mid-stage study of its 24-Valent pneumococcal conjugate vaccine candidate, VAX-24, in adults aged 6 more_horizontal
By MarketBeat
April 18, 2023
Still 50% Upside To Go, Wall Street Is Getting Vaxcyte Right
When SVB Securities analyst David Risinger reiterated his bullish opinion on Vaxcyte, Inc. (NASDAQ: PCVX) last week, few investors noticed. The stock more_horizontal
By GlobeNewsWire
April 16, 2023
Vaxcyte to Host Webcast and Conference Call to Discuss Results from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate in Adults Aged 65 and Older and Full Six-Month Safety Data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fide more_horizontal
By GlobeNewsWire
April 16, 2023
Vaxcyte to Host Webcast and Conference Call to Discuss Results from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate in Adults Aged 65 and Older and Full Six-Month Safety Data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fide more_horizontal
By GlobeNewsWire
April 16, 2023
Vaxcyte to Host Webcast and Conference Call to Discuss Results from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate in Adults Aged 65 and Older and Full Six-Month Safety Data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fide more_horizontal
